Arrowhead Pharmaceuticals Inc. [ARWR] shares are up more than 29.45% this year and recently increased 0.06% or $3.03 to settle at $47.49. Analysts expect ARWR to grow earnings at a 7.33% annual rate over the next 5 years. ARWR has a short ratio of 6.53. This implies that the market is currently less bullish on the outlook for ARWR.

On 8, October 2020, Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease. According to news published on Yahoo Finance, − Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD .

Analyst Birdseye View:

The most recent analyst activity for Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] stock was on May 08, 2020, when it was Upgrade with an Outperform rating from Oppenheimer, which also raised its 12-month price target on the stock to $58. Before that, on May 13, 2020, RBC Capital Mkts Recapitulated an Outperform rating and elevated its amount target to $62. On April 15, 2020, Cantor Fitzgerald Upgrade an Overweight rating and boosted its price target on this stock from $55 to $60. On March 24, 2020, SVB Leerink Upgrade a Mkt perform rating and increased its price target to $29. On March 17, 2020, Goldman Initiated a Neutral rating and increased its price target to $45. On January 21, 2020, SVB Leerink Initiated an Underperform rating and boosted its amount on this stock to $32. On December 13, 2019, Oppenheimer Initiated a Perform rating. On November 29, 2019, Chardan Capital Markets Reiterated a Buy rating and improved its amount target to $81.

In the past 52 weeks of trading, this stock has oscillated between a low of $19.51 and a peak of $73.72. Right now, the middling Wall Street analyst 12-month amount mark is $69.00. At the most recent market close, shares of Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] were valued at $47.49. According to the average price forecast, investors can expect a potential return of 4.87%.


Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] most recently reported quarterly sales of 27.38 billion, which represented growth of -35.80%. This publicly-traded organization’s revenue is $1,259,668 per employee, while its income is $507,275 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 29.46, 39.94, 35.83 and 39.69 respectively.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 43.60 points at 1st support level, the second support level is making up to 42.73. But as of 1st resistance point, this stock is sitting at 46.02 and at 47.57 for 2nd resistance point.

Arrowhead Pharmaceuticals Inc. [ARWR] reported its earnings at -$0.13 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.12/share signifying the difference of -0.01 and -8.30% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.2 calling estimates for -$0.11/share with the difference of -0.09 depicting the surprise of -81.80%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Arrowhead Pharmaceuticals Inc. [NASDAQ:ARWR] is 7.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.67. Now if looking for a valuation of this stock’s amount to sales ratio it’s 16.46 and it’s amount to book ratio is 11.00.

Insider Stories

The most recent insider trade was by Ferrari Mauro, Director, and it was the sale of 10000.0 shares on Oct 09. Anzalone Christopher Richard, the Chief Executive Officer, completed a sale of 50000.0 shares on Aug 13. On Jun 25, Anzalone Christopher Richard, Chief Executive Officer, completed a sale of 100000.0 shares.